Loading…
Syndax Pharmaceuticals, Inc. is projected to rise to $34.56 by 2027, a +39% move from its current price of $24.84. SNDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $24.16 | $24.84 | $25.54 | +0.02% |
| Jul 14 | $23.89 | $24.85 | $25.84 | +0.03% |
| Jul 15 | $23.69 | $24.85 | $26.07 | +0.05% |
| Jul 16 | $23.51 | $24.86 | $26.27 | +0.06% |
| Jul 17 | $23.36 | $24.86 | $26.45 | +0.08% |
| Jul 18 | $23.23 | $24.86 | $26.61 | +0.09% |
| Jul 19 | $23.11 | $24.87 | $26.76 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $23.11 | $24.87 | $26.76 | +0.11% |
| Week 2 | $22.44 | $24.89 | $27.62 | +0.22% |
| Week 3 | $21.95 | $24.92 | $28.30 | +0.33% |
| Week 4 | $21.54 | $24.95 | $28.89 | +0.43% |
| Week 5 | $21.20 | $24.97 | $29.43 | +0.54% |
| Week 6 | $20.89 | $25.00 | $29.93 | +0.65% |
| Week 7 | $20.61 | $25.03 | $30.39 | +0.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Syndy nx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer. Its lead product candidates include Revuforj (revumenib), a menin inhibitor for relapsed or refractory R/R acute leukemia, and Niktimvo (axatilimab-csfr), a colony-stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company is also developing revumenib for the treatment of R/R AML with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals, Inc. (SNDX) is a healthcare stock with a current price of $23.24 and a market cap of $2.06B. It is ranked 2029 in the market hierarchy.
The technical setup shows bullish sentiment on the near term, with RSI14 at 70, and shares trading above the 50-day (SMA50) at $19.89 and the 200-day (SMA200) at $19.78.
Support sits at $16.96 and resistance at $23.24, while the 30-day price range spans $19.63 to $27.52. The longer-term outlook is bullish, with the year-by-year forecast indicating growth from a 2026 average near $23.24 toward substantially higher levels by 2050, including a 2050 average of $252.86 and a 2050 max of $456.82.
A major floor 43.9% below — a decisive break under it would weaken the trend.
The nearest floor, 31.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 19.5% above — clearing it would confirm fresh momentum.
Key SNDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.67 | Buy | $23.58 | Buy |
| MA 10 | $22.60 | Buy | $22.67 | Buy |
| MA 20 | $20.80 | Buy | $21.51 | Buy |
| MA 50 | $20.08 | Buy | $20.83 | Buy |
| MA 100 | $21.50 | Buy | $20.71 | Buy |
| MA 200 | $19.92 | Buy | $19.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.01 | Neutral |
| Stoch RSI (14) | 54.69 | Neutral |
| CCI (20) | 104.07 | Buy |
| Williams %R (14) | -22.28 | Info |
| MACD (12,26,9) | 0.48 | Buy |
| ROC (12) | 20.40 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 77.72 | Neutral |
| TRIX (15) | 0.52 | Buy |
| Awesome (5,34) | 3.73 | Buy |
| Ultimate (7,14,28) | 67.18 | Neutral |
| Momentum (10) | 3.80 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 24.95 | Sell |
| ADX (14) | 29.22 | Buy |
| ATR (14) | 0.60 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 70 and price above key moving averages: SMA50 is $19.89 and SMA200 is $19.78.
The current price of $23.24 sits above both SMAs, signaling positive near-term momentum.
Support is at $16.96 and resistance at $23.24, with a 30-day range of $19.63 to $27.52.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.96 | $24.84 | $33.11 | 0% | Neutral | |
| $27.47 | $34.56 | $46.02 | +39% | Bullish | |
| $30.87 | $39.96 | $55.24 | +61% | Bullish | |
| $34.18 | $45.29 | $64.47 | +82% | Bullish | |
| $36.99 | $50.04 | $73.02 | +101% | Bullish | |
| $37.23 | $51.33 | $76.52 | +107% | Bullish | |
| $39.63 | $55.61 | $84.51 | +124% | Bullish | |
| $46.02 | $65.66 | $101.54 | +164% | Bullish | |
| $56.34 | $81.66 | $128.33 | +229% | Bullish | |
| $60.29 | $88.71 | $141.51 | +257% | Bullish | |
| $83.75 | $131.96 | $224.06 | +431% | Bullish | |
| $140.22 | $248.61 | $462.25 | +901% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.96 | $24.84 | $30.08 | +0.00% |
| August 2026 | $21.09 | $24.91 | $30.22 | +0.28% |
| September 2026 | $21.18 | $25.19 | $30.91 | +1.13% |
| October 2026 | $22.11 | $26.46 | $32.77 | +5.03% |
| November 2026 | $22.28 | $26.80 | $33.46 | +1.29% |
| December 2026 | $21.78 | $26.33 | $33.11 | -1.76% |
Click any year to see its month-by-month SNDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNDX price prediction for 2026 points to an average of $24.84 (low $16.96, high $33.11) — a potential gain of 0% on today's $24.84. Price action looks broadly range-bound.
In 2027, SNDX is projected to trade between $27.47 and $46.02, averaging $34.56 — a potential gain of +39% from today's $24.84. That is up +39% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Syndax Pharmaceuticals, Inc.'s 2028 outlook centres on $39.96, within a $30.87 to $55.24 range. That is up +16% on the projected 2027 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2029, SNDX could reach as high as $64.47, with a base case around $45.29 and support toward $34.18 — roughly +82% from $24.84. Buyers look set to stay in control over this stretch.
Expect SNDX to range from $36.99 to $73.02 through 2030. The $50.04 average target implies a +101% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The SNDX price prediction for 2031 points to an average of $51.33 (low $37.23, high $76.52) — a potential gain of +107% on today's $24.84. Buyers look set to stay in control over this stretch.
In 2032, SNDX is projected to trade between $39.63 and $84.51, averaging $55.61 — a potential gain of +124% from today's $24.84. That is up +8% on the projected 2031 average. Momentum favours further upside here.
Syndax Pharmaceuticals, Inc.'s 2033 outlook centres on $65.66, within a $46.02 to $101.54 range. That is up +18% on the projected 2032 average. That marks a +164% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SNDX could reach as high as $128.33, with a base case around $81.66 and support toward $56.34 — roughly +229% from $24.84. Momentum favours further upside here.
Expect SNDX to range from $60.29 to $141.51 through 2035. The $88.71 average target implies a +257% move from current prices. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SNDX price prediction for 2040 points to an average of $131.96 (low $83.75, high $224.06) — a potential gain of +431% on today's $24.84. Momentum favours further upside here.
In 2050, SNDX is projected to trade between $140.22 and $462.25, averaging $248.61 — a potential gain of +901% from today's $24.84. That is up +88% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNDX today (≈ 40.257649 SNDX) could be worth
$10,008.3
+$9,008.3 (+901%) by 2050 · US Dollar
Based on the average projected SNDX price of $248.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNDXwould be worth at today's price.
$1,000 invested in SNDX on Jul 10, 2025 (≈ 101.832997 SNDX) would be worth
$2,529.53
+$1,529.53 (+153.0%) today · 2.53× · US Dollar
Based on a SNDX entry price of $9.82 vs. today's $24.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.82 | $1,138.41 | +13.8% |
| 1 month ago | $17.58 | $1,412.97 | +41.3% |
| 3 months ago | $24.44 | $1,016.37 | +1.6% |
| 6 months ago | $20.72 | $1,198.84 | +19.9% |
| 1 year ago | $9.82 | $2,529.53 | +153.0% |
| All time (5.0y) ago | $16.21 | $1,532.39 | +53.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNDX forecast.
Our base-case forecast reaches $50.00 around 2030.
Implied market cap at $50.00: $4.43B
The year-by-year forecast portrays a persistent bullish trajectory across the horizon. In 2026, the min, avg, and max are $16.96, $23.24, and $31.05 respectively, with a neutral sentiment and ROI of 0.
From 2027 onward, the forecast shows sustained gains: 2027 min $26.20, avg $32.74, max $43.19, ROI 40.9, sentiment BULLISH; 2028 min $29.52, avg $37.85, max $51.71, ROI 62.9, sentiment BULLISH; 2029 min $32.97, avg $43.20, max $60.65, ROI 85.9, sentiment BULLISH; 2030 min $36.16, avg $48.29, max $69.38, ROI 107.8, sentiment BULLISH.
The forecast continues to rise with 2031 min $36.69, avg $49.84, max $73.07, ROI 114.5; 2032 min $39.62, avg $54.69, max $81.65, ROI 135.3; 2033 min $46.51, avg $65.17, max $98.90, ROI 180.4; 2034 min $56.25, avg $79.96, max $123.19, ROI 244.1; 2035 min $60.48, avg $87.15, max $136.17, ROI 275.
Beyond the mid-2030s, the gains accelerate further: 2040 min $86.36, avg $132.37, max $219.39, ROI 469.6, sentiment BULLISH; and by 2050 min $148.45, avg $252.86, max $456.82, ROI 988, sentiment BULLISH.
These figures illustrate a long-run bullish outlook, though they are estimates and not guarantees, and investors should consider the inherent uncertainty and volatility in future price movements.
Tap a question to reveal the answer.
2030 min: $36.16; avg: $48.29; max: $69.38; ROI: 107.8; sentiment: BULLISH.
The year-by-year forecast shows a bullish sentiment across multiple years, with 2027 avg $32.74, 2028 avg $37.85, 2029 avg $43.20, 2030 avg $48.29, 2040 avg $132.37, and 2050 avg $252.86, with ROI values up to 988. These are estimates, not guarantees.
Yes. The forecast lists 2034 max $123.19 and 2035 max $136.17, indicating a path above $100 by 2034 per the provided numbers.
Current price: $23.24; Market cap: $2.06B.
RSI14: 70; SMA50: $19.89; SMA200: $19.78; Support: $16.96; Resistance: $23.24; 30-day range: $19.63-$27.52.
Syndax Pharmaceuticals, Inc. Community Discussion
0Share your Syndax Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.